| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC2973 |
| Trial ID | NCT05296564 |
| Disease | Bladder Urothelial Carcinoma | Mediastinum Neuroblastoma | Ovary Cancer | Lung Non-Small Cell Carcinoma | Synovial Sarcoma | Melanoma | Childhood Soft Tissue Sarcoma | Triple-Receptor Negative Breast Cancer |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| HLA | HLA-A*02:01|HLA-A*02:06 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers |
| Year | 2022 |
| Country | Israel |
| Company sponsor | Hadassah Medical Organization |
| Other ID(s) | 0752-20-HMO |
| Cohort 1 | |||||||||||
|
|||||||||||